Kornimate/medical-research-clean huggingface dataset:
shock waves in knee arthritis

Conditions: Arthritis of Knee

Summary: pathological arthritis is a degenerative disease affecting the joints, characterized by pain, limitation of movement up to ankylosis and disability. treatment is aimed at reducing pain and slowing the loss of functionality of the district. among conservative treatments, pharmacological options (nsaids, cortisone, contrasupplements, hyaluronic acid) and non-pharmacological options (therapeutic exercise, physical therapy, orthosis, etc.) are indicated. in cases not responding to conservative treatments, surgical treatment will be necessary with prosthetic replacement of the joint district.

in recent years, shock wave therapy has received a lot of interest in the treatment of numerous musculoskeletal pathologies. this physical therapy exploits the cavitational effect induced on the tissues which translates into neo-angiogenic, anti-inflammatory, regenerative and analgesic action. until now, the indication has been reserved for the treatment of tendinopathies and delayed consolidation of fractures. pre-clinical research is also paving the way for the treatment of cartilage pathologies; in fact, after the stimulation of the chondrocyte, a modulation of the phlogogenic cytokines has been found, supporting a slowing down of the progression of the arthritic pathology. the first clinical experiences on arthritic models, such as rhizarthrosis, allow to support the indication also on the pathological model of gonarthrosis. the aim of this study is to verify the effects of shock wave therapy in the patient affected by gonarthrosis, monitoring the action on pain, functionality and tissue district changes.

Eligibility criteria:
inclusion criteria: * persistent knee pain for at least 3 months, measured with a vas scale of 4 or higher, * clinical and radiological diagnosis confirming knee osteoarthritis grade 2 and 3 based on the kellgren-lawrence system, * no history of physical therapy in the last 3 months, * no infections, tumors in the treatment area of the knee, * no pathology other than osteoarthritis that could cause knee pain, * no pathology of the lumbar spine or hip that could refer knee pain, * free from any condition that prevents participation in exercise or physical therapy willing to participate regularly in the treatment programs were included in the study. exclusion criteria: * inability to walk, * a history of clinically symptomatic spinal stenosis or lumbar radiculopathy, * evidence of a neurological disorder based on history or physical examination, * generalized pain or fibromyalgia, * secondary osteoarthritis (to metabolic or rheumatologic disease), * administration of intra-articular injections (anesthetic, hyaluronic acid, cortisone) of the knee in the last 6 months, * use of nsaids, paracetamol or topical agents in the previous week, * a previous history of surgery involving the knee joint, * contraindications to physical therapy (pm, epilepsy, neoplasia, coagulopathy, pregnancy).

Keywords: shock waves conservative treatment
attention bias modification for reducing health anxiety during the coronavirus pandemic

Conditions: Anxiety

Summary: the outbreak of the 2019 coronavirus (covid-19) pandemic is a major stressor leading to increased levels of anxiety, and specifically, an excessive fear of being infected and affected by the disease among major parts of the population. at the same time, the access to mental health services is limited due to the lockdown policy applied in many countries worldwide, warranting the development of home-delivered interventions aimed at reducing stress and anxiety symptoms. attention bias modification (abm) has been found to be an efficacious computerized intervention to reduce anxiety symptoms. in this open pilot trial, participants reporting on elevated levels of health anxiety concerning the covid-19 epidemic will receive one session of abm over 5 consecutive days (5 sessions total). symptoms of health anxiety, state anxiety, generalized anxiety, and depression will be measured at baseline and post-treatment.


Eligibility criteria:
inclusion criteria: * 3 or more symptoms (out of 7) reported in the covid-19 anxiety inventory with a score of 4 or 5. * fluent hebrew * having a pc computer at home with internet access exclusion criteria: * a diagnosis of dyslexia or other reading disability
biopsy after radioembolization to identify changes in tumor cells from the radiation

Conditions: Colon Cancer Liver Metastasis; Colon Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Liver Metastasis Colon Cancer; Colorectal Cancer

Summary: the purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure. this research may improve the way that radioembolization is performed, which could help people whose cancer has spread to the liver. the research may also provide information about how tumors respond to radioembolization.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * eastern cooperative oncology group (ecog) performance status 0-2 * histologically confirmed primary adenocarcinoma of the colon or rectum * clm considered unresectable or not amenable to percutaneous ablation * existent tissue samples from a standard of care biopsy of the target tumor within 42 days prior to treatment or clinical indication for biopsy at the time of the treatment under the institutional guidelines for progression of disease. * adequate blood cell counts (wbc \> 1.5 x 109/l, platelet count \> 50 x 109/l) * adequate renal function (creatinine \< 1.5 mg/dl) * total bilirubin level ≤ 1.5 mg/dl additional inclusion criteria for patients, undergoing 90y radiation segmentectomy: a. patients not amenable to surgery or thermal ablation exclusion criteria: study exclusion criteria will be similar to general tare exclusion criteria, which are as follows: * prior hepatic radiotherapy (the lesion / lobe being treated cannot have had prior treatment with radiotherapy - untreated lesions / lobes in the liver may be evaluated under the protocol) * severe cirrhosis * severe portal hypertension * uncorrectable flow to the gastrointestinal tract and/or \>30 gy (or \>50 gy in multiple sessions) radiation absorbed dose to the lungs all patients with liver-dominant disease will be considered candidates for tare even in the face of oligometastatic (up to 5 sites) extrahepatic disease, that is stable or controlled by chemotherapy.

Keywords: colorectal liver metastases transarterial radioembolization y90 tare colon cancer liver metastasis colon cancer adenocarcinoma of the colon adenocarcinoma of the rectum colorectal cancer memorial sloan kettering cancer center 20-355
study to assess the safety and tolerability of multiple ascending doses of regn1500

Conditions: Metabolic Disorders

Summary: this is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetic (pk), immunogenicity, and pharmacodynamic (pd) effects of regn1500 in patients with a metabolic disorder.


Eligibility criteria:
inclusion criteria: * provide signed informed consent * otherwise healthy men and women ages 18 to 65 years, inclusive * body mass index of 18.0 kg/m2to 38.0 kg/m2, inclusive * normal standard 12-lead ecg * willing to refrain from the consumption of alcohol for 24 hours prior to each study visit * willing to consistently maintain his/her usual diet for the duration of the study * willing to refrain from strenuous exercise for the duration of the trial * willing and able to comply with clinic visits and study-related procedures * for sexually active men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant) during the full duration of the study. exclusion criteria: * any clinically significant abnormalities observed during the screening visit * history of drug or alcohol abuse within 1 year of screening * receipt of another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer), of the investigational drug prior to the screening visit. * significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that may adversely affect the subjects participation in this study * known history of human immunodeficiency virus (hiv) antibody; and/or positive hepatitis b surface antigen (hbsag), and/or positive hepatitis c antibody (hcv) at the screening visit * hospitalization for any reason within 60 days of screening * history or presence of malignancy within 5 years prior to the screening visit (other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, and/or localized carcinoma in situ of the cervix * any medical or psychiatric condition which, in the opinion of the investigator, would place the subject at risk, interfere with participation in the study or interfere with the interpretation of the study results * any subject who is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff directly involved in the conduct of the protocol, or family member of staff involved in the conduct of the protocol * pregnant or breast-feeding women note: the information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial and not all inclusion/ exclusion criteria are listed.
phase ib study using sunitinib plus radiation therapy for cancer patients

Conditions: Cancer; Head and Neck Cancer; Pelvic Cancer; Nervous System Neoplasms; Thoracic Neoplasms

Summary: this study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

the combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.

Eligibility criteria:
inclusion criteria: * minimum 2 week course of radiation therapy * solid tumors of the central nervous system, head and neck, thorax, and pelvis exclusion criteria: * major surgery or radiation therapy within 4 weeks starting study treatment * grade 3 hemorrhage within 4 weeks

Keywords: solid tumor central nervous system head and neck thorax pelvic area
study of olopatadine hcl ophthalmic solutions compared to vehicle using the conjunctival allergen challenge (cac) model of acute allergic conjunctivitis in japanese subjects

Conditions: Allergic Conjunctivitis

Summary: the purpose of the study is to demonstrate safety and efficacy of olopatadine 0.2% compared to its vehicle in japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge (cac) test.


Eligibility criteria:
inclusion criteria: * japanese ethnicity. * seasonal allergic conjunctivitis--asymptomatic. * other protocol-defined inclusion criteria may apply. exclusion criteria: * manifest signs and symptoms of clinically active allergic conjunctivitis in either eye (\>1 for redness in any of the 3 vessels beds - conjunctival, episcleral, ciliary - or itching \>0) at the start of any visit. * other protocol-defined exclusion criteria may apply.

Keywords: allergies ocular
intraperitoneal bupivacaine with magnesium or nalbuphine for postoperative pain control in laparoscopic hysterectomy

Conditions: Anesthesia

Summary: the purpose of this study is to compare between the addition of mg sulphate or nalbuphine to intraperitoneal bupivacaine installation in laparoscopic hysterectomy for postoperative pain control and their relative adverse effects.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i and ii * scheduled for laparoscopic hysterectomy exclusion criteria: * asa physical status more than ii * obesity (body mass index higher than 30 kg/ m2) * history of chronic opioids intake * known hypomagnesaemia or hypermagnesaemia * chronic alcoholism * heart block * renal failure * patients with history of left ventricular failure * patients taking beta-blocking drugs * allergy to the study drugs * if surgery changed to open hysterectomy,
high intensity functional image guided vmat lung evasion

Conditions: Non Small Cell Lung Cancer Stage III

Summary: this study is being performed to assess the feasibility of adapting radiotherapy plans based on functional lung information and increasing the dose to the primary tumour. this is a single arm interventional pilot study involving 20 patients. aims primary: to assess the feasibility of using ventilation and perfusion positron emission computed tomography (v/q pet/ct) scans to adapt radiotherapy plans using volumetric modulated arc therapy (vmat) to avoid regions of functional lung and deliver a higher dose to the primary tumour secondary: to assess the incidence of acute and late radiotherapy toxicities, to quantify regional ventilation loss and regional perfusion loss on post treatment v/q pet/ct, to assess associations of v/q pet/ct with other functional lung imaging techniques, to assess overall survival, progression free survival and quality of life outcomes. participants: 20 patients stage iiia-c non-small cell lung cancer for curative intent radiotherapy. methods: all patients will receive functional lung adapted 60 gray (gy) in 30 fractions to the primary and nodal planning target volume with a simultaneous integrated boost to the primary tumour to a total dose 69gy in 30 fractions. expected outcomes: that functionally adapted lung radiotherapy using v/q pet/ct imaging and vmat planning is technically feasible.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * written informed consent has been provided. * histologically or cytologically confirmed non-small cell lung cancer * eastern cooperative oncology group (ecog) performance status 0-2 within 2 weeks prior to registration * locally advanced disease (stage iiia, iiib, iiic as per american joint committee on cancer ajcc, 8th ed.) as confirmed on staging 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (fdg) pet/ct * no evidence of metastatic intracranial disease on ct brain with contrast or mri * willing to participate in the full follow up schedule * planned for treatment with curative intent exclusion criteria: * participant is not able to tolerate supine position on pet/ct bed for the duration of the pet/ct acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from intensive care unit) or is unable to attend full course of follow up visits * pregnancy or breast-feeding * if history of a prior extra thoracic invasive malignancy (except non-melanomatous skin cancer) must be free from recurrence for a minimum of 3 years at the time of registration * prior radiotherapy to the lungs or mediastinum (a history of prior breast radiotherapy is not an exclusion) * prior known history of interstitial lung disease \* a history of renal impairment or reaction to iodine contrast is not an exclusion criteria, if a patient has medical comorbidities that exclude the use of iodine contrasts, these exploratory investigations can be omitted.
measuring temperatures of tissues during endoscopy

Conditions: Carcinoma, Undifferentiated

Summary: previous studies have indicated that tumors are warmer than the surrounding tissues. we want to ascertain that this is true for tumors in the gi tract. if so, a thermal camera in an endoscope may aid the diagnosis of tumors. the experiment entails inserting a cannula sheathed thermocouple into the work canal of an endoscope or a colonoscope. the examining physician will bring the distal end to touch the tumors he finds and their adjacent tissues, noting their respective temperatures. this experiment must be conducted before embarking on the complicated and costly project of producing a tiny thermal camera which will be able to navigate the gi tract.


Eligibility criteria:
inclusion criteria: * consenting adults exclusion criteria: * none

Keywords: gi tract tumors temperatures
clinical application of mr-pet in non-small cell lung cancer: diagnosis, treatment outcome, and prognosis prediction

Conditions: Non-small Cell Lung Cancer

Summary: it is a study that hypothesize that mr/pet can have better information than current ct image study, about the medical or surgical treatment outcome of lung cancer

the investigators analyze tumor size、adcmean、adcmin、dce、suvmax、suvmin、etc in mr/pet study，to compare its efficacy with other image studies in tumor malignancy grade, systemic involvement detection, treatment outcome after medical target therapy and treatment outcome after surgery.

Eligibility criteria:
inclusion criteria: 1. age: \> 20 years old. 2. patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells) 3. patients voluntarily to join this study and signed informed consents. exclusion criteria: 1. any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves 2. patients with claustrophobia to mri examination 3. patients who are reluctant to comply with follow-up and subsequent examination 4. the other condition that do not meet the inclusion criteria. 5. pregnancy. 6. age \< 20 years old.

Keywords: mr/pet non-small cell lung cancer (nsclc)
effect of samples on acne treatment with epiduo® gel

Conditions: Acne Vulgaris

Summary: the purpose of this study is to compare adherence to treatment and efficacy with epiduo® gel in patients with mild to moderate acne who receive a medication sample and instructions on proper application with their stock size medication tube versus patients who receive only the stock size medication tube.

adapalene topical gel is a vitamin a type product in a water-based gel that is applied to the skin. it is approved by the united states food and drug administration (fda) for the treatment of acne. benzoyl peroxide is a medication applied to the skin that is also approved by the fda for the treatment of acne and has anti-bacterial properties. the purpose of this study is to evaluate the safety and effectiveness of a drug called epiduo® gel 0.1%/2.5% for the treatment of acne vulgaris.epiduo® is a combination of adapalene and benzoyl peroxide. this combination drug is approved by the fda for sale in the united states for use in individuals with acne who are over the age of 12.

Eligibility criteria:
inclusion criteria: * male or female subject with mild to moderate acne, aged 12 and older, who agrees to participate and provides written consent. * have an acne global assessment (aga) of mild to moderate acne (an aga score of 2 or 3) exclusion criteria: * presence of a concurrent medical condition or skin condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments. * subjects with known allergy or sensitivity to epiduo® gel (or benzoyl peroxide gel) or components therein, including adapalene or benzoyl peroxide * female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. reliable methods of birth control are: abstinence (not having sex), oral contraceptives, intrauterine device (iud), depo-provera, tubal ligation, or vasectomy of the partner (with confirmed negative sperm counts) in a monogamous relationship (same partner). an acceptable, although less reliable, method involves the careful use of condoms and spermicidal foam or gel and/or a cervical cap or sponge. nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.

Keywords: adherence adapalene benzoyl peroxide sample topical treatment
comparison study for bile reflux and gastric stasis in patients after distal gastrectomy

Conditions: Stomach Cancer; Gastrectomy

Summary: the purpose of this study is to evaluate the degree of bile reflux and gastric stasis according the reconstruction methods after distal subtotal gastrectomy for gastric cancer, and to find out the proper method. we collect ninety patients who undergo distal gastrectomy for gastric cancers for this study from 5 institutions and randomly divide into 3 groups according to reconstruction methods: 1) billroth-ii (b-ii), 2) roux en y gastrojejunostomy (ry-gj) and 3) uncut roux en y gastrojejunostomy (uncut ry-gj).

patients who have undergone gastrectomy for gastric cancer might be developed various symptoms by gastric stasis and bile reflux, it so called "post-gastrectomy syndrome", because of the diminishment of stomach capacity, the decrease of expulsive ability and the change of food passage. until now, that had been accepted as the inevitable results after gastric resection. however, the survival rate has recently been increased owing to the increased proportion of early gastric cancer. and thus, to improve the quality of life of patients, many researchers have been actually studying for the reconstruction methods which are able to minimize the symptom by gastrectomy, but it is dissatisfied until now. thus, the purpose of this study is to evaluate the degree of bile reflux and gastric stasis according the reconstruction methods after distal subtotal gastrectomy for gastric cancer, and to find out the proper method. we collect ninety patients who undergo distal gastrectomy for gastric cancers for this study from 5 institutions and randomly divide into 3 groups according to reconstruction methods: 1) billroth-ii (b-ii), 2) roux en y gastrojejunostomy (ry-gj) and 3) uncut roux en y gastrojejunostomy (uncut ry-gj). we evaluate the postoperative morbidity rate and then the degree of bile reflux, gastric emptying time and quality of life through long term follow-up using the gastrofiberscope, survey and so on. from this study, we would suggest the standard reconstruction procedure after distal gastrectomy.

Eligibility criteria:
inclusion criteria: * patients who underwent distal gastrectomy for adenocarcinoma of stomach with following criteria: 1. have cancer located in middle or distal portions 2. preoperative staged as ct1n0m0 or ct2n0m0 by computed tomography and gastrofiberscope (endoscopic ultrasound, optionally) 3. have the american society of anaesthesiologists (asa) score of three and less exclusion criteria: * patients following criteria: 1. have simultaneously other cancer 2. underwent cancer therapy (radiologic or immunologic or chemotherapeutic method) at past time 3. have systemic inflammatory disease 4. have upper gastrointestinal surgery 5. have the gastric cancer with obstruction 6. get pregnancy 7. are treating diabetics with insulin 8. are participating or participated within 1 month in other clinical trials 9. have bmi less than 25 10. are expected to perform laparoscopy assisted gastrectomy

Keywords: stomach cancer gastrectomy postgastrectomy syndrome